Blinatumomab

Blincyto 12.5 mcg/mL poeder voor concentraat voor oplossing voor infusie

Poeder voor concentraat voor oplossing voor infusieNetherlandsAuthorisedAuthorised 23 Nov 2015

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

BlincytoEuropean UnionAuthorised

BlincytoBrazil · Amgen Biotecnologia do Brasil Ltda.Same brand
BlincytoCanada · 38.5 MCG / VIAL · Powder For Solution · Amgen Canada INCSame brand
Blincyto 38,5mcg de polvo para concentrado y solucion para solucion para perfusionSpain · 38,5 µg · polvo para concentrado y solución para solución para perfusion · Amgen Europe B.V.Same brand
BlincytoEuropean Union · Amgen Europe B.V.Same brand
BlincytoCroatiaSame brand
BlincytoItaly · polvere per concentrato e soluzione per soluzione per infusione · Amgen Europe B.V.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Blinatumomab

Blincyto 12.5 mcg/mL poeder voor concentraat voor oplossing voor infusie

Poeder voor concentraat voor oplossing voor infusieNetherlandsAuthorisedAuthorised 23 Nov 2015

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

BlincytoEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

BLINCYTO 38,5 microgrameRomania · 38,5micrograme · pulb. pt. conc. si sol. pt. sol. perf. · Amgen Europe B.V.

BlincytoSaudi Arabia · Boehringer Ingelheim Pharma GmbH & Co. KG

Blincyto Powder for Infusion 35 MCG/VialSingapore · 55.0 μg/mL · injection, powder, lyophilized, for solution · Amgen Biotechnology Singapore Pte LTD

BlincytoUnited States · 35MCG · injectable · Amgen

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

College ter Beoordeling van Geneesmiddelen

College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.

Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim · Added 8 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Blinatumomab
Dosage form: Poeder voor concentraat voor oplossing voor infusie
Route: Intraveneus gebruik
Register: Netherlands (CBG-MEB)
Status: Authorised
Status in the register: Ingeschreven
Authorised: 23 Nov 2015
Registration: EU/1/15/1047
Marketing authorisation holder: Amgen Europe B.V.
ATC code: L01FX07
Group: Antineoplastic and immunomodulating agents
Procedure: EU centralised
Supply: Uitsluitend recept
EMA product number: EMEA/H/C/003731
EU number: EU/1/15/1047